Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

170
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
170
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

217
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
217
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

305
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
305
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot study of gene mutations associated with Lynch syndrome in Slovak patients with breast cancer.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2023
Same author

PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.

Physiological research·2023
Same author

Importance of the genetics in the diagnostics of hydatidiform mole.

Ceska gynekologie·2021
Same author

Murine experimental models for studying the pathogenesis of coxsackieviruses.

Acta virologica·2020
Same author

Schiff base Cu(II) complexes as inhibitors of proteasome in human cancer cells.

Bratislavske lekarske listy·2019
Same author

Various AKIP1 expression levels affect its subcellular localization but have no effect on NF-kappaB activation.

Physiological research·2019

Related Experiment Video

Updated: Jul 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Chelators as Antineuroblastomas Agents.

C W D'Acunto1, H Gbelcová, R Kaplánek

  • 1Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic; Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic. helena.gbelcova@fmed.uniba.sk.

Physiological Research
|October 27, 2023
PubMed
Summary

New chelator compounds, HLZ, show potential against neuroblastoma. These molecules effectively inhibit MYCN-non-amplified neuroblastoma cells by halting cell cycle progression and activating specific cell signaling pathways.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.2K

Related Experiment Videos

Last Updated: Jul 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Neuroblastoma is a significant pediatric cancer, with aggressive forms often resistant to chemotherapy.
  • MYCN gene amplification is a key indicator of poor prognosis in neuroblastoma.
  • The anticancer potential of chelating compounds in neuroblastoma remains largely unexplored.

Purpose of the Study:

  • To investigate the efficacy of novel chelator compounds, HLZ (1-hydrazino phthalazine), against neuroblastoma cell lines.
  • To determine the effect of HLZ on neuroblastoma cell proliferation, cell cycle, apoptosis, and ROS production.
  • To elucidate the mechanism of action of HLZ in neuroblastoma cells, focusing on MYCN amplification status.

Main Methods:

  • Utilized three neuroblastoma cell lines with varying MYCN amplification levels.
  • Assessed cell proliferation using WST-1 and methylene blue assays.
  • Analyzed cell cycle distribution via flow cytometry.
  • Investigated apoptosis through specific pharmacological inhibitors and Western blot analysis.
  • Measured ROS production using a fluorometric assay.

Main Results:

  • HLZ compounds demonstrated efficacy exclusively in MYCN-non-amplified neuroblastoma cells.
  • HLZ treatment resulted in cell cycle arrest at the G0/G1 phase in sensitive cell lines.
  • The mechanism of action involved the activation of cell signaling pathways, including protein kinase C.

Conclusions:

  • Novel HLZ chelators exhibit selective anticancer activity against MYCN-non-amplified neuroblastoma.
  • HLZ represents a potential therapeutic strategy for a subset of neuroblastoma patients.
  • Further research into HLZ's mechanism and therapeutic application is warranted.